Diagnosis of pheochromocytoma and paraganglioma. Focus on chromogranin A

Q4 Medicine
E. Kravchuk, U. Tsoy, A. S. Kruk, E. Vasilyeva, E. Grineva
{"title":"Diagnosis of pheochromocytoma and paraganglioma. Focus on chromogranin A","authors":"E. Kravchuk, U. Tsoy, A. S. Kruk, E. Vasilyeva, E. Grineva","doi":"10.18705/1607-419x-2023-29-1-68-78","DOIUrl":null,"url":null,"abstract":"Objective. To analyze the results of a laboratory examination for chromogranin A in the blood performed in the laboratory at Almazov National Medical Research Centre in patients with confirmed diagnosis of pheochromocytoma/paraganglioma (PPGL) and in patients with unconfirmed neuroendocrine tumor based on the results of a comprehensive examination and to determine the possibilities of this method in the diagnosis of PPGL. Design and methods. A single-center retrospective cohort study was conducted. Electronic medical histories of patients with valid chromogranin A blood test in the period from 2015 to 2021 were studied. The patients included in the study were divided into 2 groups. Group 1 (study group) included 51 patients with a confirmed diagnosis of PPGL, and Group 2 (control group) included 120 patients, who were examined for suspected neuroendocrine tumor, but the diagnosis was not confirmed. The threshold value of chromogranin A was determined using ROC-analysis, the presence of PPGL was selected as a dependent variable. Results. The median of chromogranin A in the study group was 495,93 µg/l (0–100). According to the ROC-analysis, the optimal point of separation of the chromogranin A value for the diagnosis of PPGL with a test sensitivity of 82,4 %, specificity of 94,2 % (area under curve AUC — 0,939, standard error — 0,024, 95 % confidence interval — 0,892–0,986, p < 0,001) was 97,2 µg/l. After dividing patients with PPGL into 3 subgroups, depending on the size of the adrenal gland formation and the prevalence of the lesion according to computer tomography (less than 5 cm — subgroup 1, 5 cm or more — subgroup 2, multiple lesion — subgroup 3), the sensitivity of the threshold value of chromogranin A 97 µg/l in subgroup 1 was 70 %, in subgroup 2 — 95 % and in subgroup 3 — 82 %. Conclusions. Performing a blood test for chromogranin A can be used as an effective marker of PPGL, complementing the standard methods of laboratory diagnostics. This indicator may be an additional factor in the diagnosis of PPGL, especially in the presence of large formations, but the absence of an increase in chromogranin A should not be used to exclude the diagnosis.","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"77 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arterial Hypertension (Russian Federation)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18705/1607-419x-2023-29-1-68-78","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective. To analyze the results of a laboratory examination for chromogranin A in the blood performed in the laboratory at Almazov National Medical Research Centre in patients with confirmed diagnosis of pheochromocytoma/paraganglioma (PPGL) and in patients with unconfirmed neuroendocrine tumor based on the results of a comprehensive examination and to determine the possibilities of this method in the diagnosis of PPGL. Design and methods. A single-center retrospective cohort study was conducted. Electronic medical histories of patients with valid chromogranin A blood test in the period from 2015 to 2021 were studied. The patients included in the study were divided into 2 groups. Group 1 (study group) included 51 patients with a confirmed diagnosis of PPGL, and Group 2 (control group) included 120 patients, who were examined for suspected neuroendocrine tumor, but the diagnosis was not confirmed. The threshold value of chromogranin A was determined using ROC-analysis, the presence of PPGL was selected as a dependent variable. Results. The median of chromogranin A in the study group was 495,93 µg/l (0–100). According to the ROC-analysis, the optimal point of separation of the chromogranin A value for the diagnosis of PPGL with a test sensitivity of 82,4 %, specificity of 94,2 % (area under curve AUC — 0,939, standard error — 0,024, 95 % confidence interval — 0,892–0,986, p < 0,001) was 97,2 µg/l. After dividing patients with PPGL into 3 subgroups, depending on the size of the adrenal gland formation and the prevalence of the lesion according to computer tomography (less than 5 cm — subgroup 1, 5 cm or more — subgroup 2, multiple lesion — subgroup 3), the sensitivity of the threshold value of chromogranin A 97 µg/l in subgroup 1 was 70 %, in subgroup 2 — 95 % and in subgroup 3 — 82 %. Conclusions. Performing a blood test for chromogranin A can be used as an effective marker of PPGL, complementing the standard methods of laboratory diagnostics. This indicator may be an additional factor in the diagnosis of PPGL, especially in the presence of large formations, but the absence of an increase in chromogranin A should not be used to exclude the diagnosis.
嗜铬细胞瘤和副神经节瘤的诊断。重点关注嗜铬粒蛋白A
目标。分析在Almazov国家医学研究中心实验室对确诊为嗜铬细胞瘤/副神经节瘤(PPGL)的患者和根据综合检查结果未确诊为神经内分泌肿瘤的患者进行的血液中嗜铬粒蛋白a的实验室检查结果,并确定该方法在诊断PPGL中的可能性。设计和方法。本研究采用单中心回顾性队列研究。对2015 ~ 2021年有效嗜铬粒蛋白A血检患者的电子病史进行研究。纳入研究的患者分为两组。1组(研究组)有51例确诊为PPGL的患者,2组(对照组)有120例疑似神经内分泌肿瘤但未确诊的患者。采用roc分析确定嗜铬粒蛋白A的阈值,选择PPGL的存在作为因变量。结果。研究组嗜铬粒蛋白A的中位数为495,93µg/l(0 ~ 100)。roc分析结果显示,色粒蛋白A诊断PPGL的最佳分离点为97.2µg/l,检测灵敏度为82.4%,特异度为94.2%(曲线下面积AUC为0.939,标准误差为0.024,95%置信区间为0.892 ~ 0.986,p < 0.001)。将PPGL患者根据肾上腺形成的大小和计算机断层显示的病变的患病率分为3个亚组(小于5 cm -亚组1,大于5 cm -亚组2,多发病变-亚组3),亚组1中嗜铬粒蛋白A 97 μ g/l的阈值敏感性为70%,亚组2 - 95%,亚组3 - 82%。结论。进行嗜铬粒蛋白a的血液检查可作为PPGL的有效标记物,补充实验室诊断的标准方法。这一指标可能是诊断PPGL的一个额外因素,特别是在存在大形成的情况下,但嗜铬粒蛋白A没有增加不应被用来排除诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Arterial Hypertension (Russian Federation)
Arterial Hypertension (Russian Federation) Medicine-Cardiology and Cardiovascular Medicine
CiteScore
0.90
自引率
0.00%
发文量
38
期刊介绍: The main aims of the Journal include collecting and generalizing the knowledge in hypertensiology; education and professional development of cardiologists and medical doctors of other specialties, who deal with different issues regarding diagnostics, management and prevention of hypertension in both clinical practice and research. The Journal also calls attention to the most urgent and up-to-date questions in hypertensiology, cardiology and related sciences. There are additional objectives, such as increasing the availability, accessibility and recognition of Russian medical scientific achievements at the international level by improving the quality of the publication and the way they are presented; enabling the exchange of opinions and information between scientists and their wider communication. The main criteria for publication selection fit with the mentioned objectives and include currency, singularity, scientific and practical novelty, applied relevance etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信